Cancer Cell Destruction Equipment & Supplies
21 equipment items found
Manufactured by:Oxford Vacmedix UK Limited based inOxford, UNITED KINGDOM
In the image below the Recombinant Overlapping Peptide is the “Antigen” being presented to the T Cell Receptor (TCR). This then triggers the growth of T Cells that will recognise the same marker on cancer cells leading to their destruction. ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
This technology arms the patient’s own T cells with CARs, which enable them to “seek and destroy” cancer ...
by:Pars Isotope Co based inTehran, IRAN
Lu-177-PSMA is a theranostic radiopharmaceutical designed for the treatment of metastatic prostate cancer. Employing the Peptide Receptor Radionuclide Therapy (PRRT) technique, it selectively targets and binds to prostate tumor cells, facilitating the destruction of malignant cells. This unique action stems from its ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the ...
Manufactured by:OncoVITA based inParis, FRANCE
Oncovita’s MeasovirTM proprietary platform relies on a DNA plasmid vector that expresses a modified measles Schwarz virus antigenome able to generate recombinant viruses by using a clonal reverse genetics system. This versatile plug-and-play platform allows producing new viruses expressing very large amounts of additional genetic ...
by:TAE Life Sciences (TLS) based inFoothill Ranch, CALIFORNIA (USA)
Gordon Locher first proposed Boron Neutron Capture Therapy (BNCT) in 1936. Clinical investigation and treatments were first introduced in the USA in the 1950s and showed promising results. Historically, BNCT clinical studies have been carried out using boronophenylalanine (BPA) and neutrons derived from the core of a nuclear reactor. While the clinical outcomes have been encouraging, the ...
by:Pars Isotope Co based inTehran, IRAN
The PARS-LUTOTATE theranostic radiopharmaceutical kit is an innovative solution formulated as a single vial for the effective treatment of neuroendocrine tumors. It utilizes the Lu-177 radioisotope, enabling the radiopharmaceutical to selectively target neuroendocrine tumor cells, facilitating their complete destruction. This procedure not only assists in ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
The company´s proprietary platform technology is based on the discovery of a novel tumor-specific marker - a membrane-expressed form of heat shock protein 70 (Hsp70). Membrane Hsp70 is most frequently expressed on a variety of different tumor types including lung, colon, breast, head and neck, stomach, pancreas carcinomas, malignant melanoma, and hematological diseases, but never on the ...
Manufactured by:Tactiva Therapeutics based inBuffalo, NEW YORK (USA)
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, billions of cancer fighting immune cells are manufactured in a special facility, and given back to the ...
Manufactured by:Greenwich LifeSciences, Inc. based inHouston, TEXAS (USA)
Following breast cancer surgery, a HER2/neu 3+ patient receives trastuzumab (Genentech/Roche’s Herceptin, a monoclonal antibody treatment that targets the HER2/neu protein) in the first year and then hopes that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years. Our immunotherapy, GP2, may be synergistic with Herceptin. GP2 is a nine ...
by:Theralase Technologies Inc. based inToronto, ONTARIO (CANADA)
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients globally. Theralase is dedicated to safely and effectively destroying cancer through the research, development and commercialization of light activated ...
Manufactured by:Elthera AG based inSchlieren, SWITZERLAND
L1 cell adhesion molecule (L1CAM) is a cell surface protein which is aberrantly expressed in many different tumor types including pancreatic, ovarian, breast, lung, and colorectal cancer. L1CAM expression increases the malignancy of these tumors by promoting cellular proliferation, metastatic spread, tumor angiogenesis, and resistance to chemotherapy. Accordingly, L1CAM-positive tumors ...
Manufactured by:BriaCell Therapeutics Corp. based inWest Vancouver, BRITISH COLUMBIA (CANADA)
The mechanism of action of Bria-IMT™/Bria-OTS™ is currently under investigation. We believe that Bria-IMT™/Bria-OTS™, activates the patient’s immune system to recognize tumor cells and destroy them. We hypothesize that Bria-IMT™/Bria-OTS™, exert their action by stimulating the antigen-presentation system (i.e. the system that presents antigen material on ...
Manufactured by:Galvanize Therapeutics, Inc. based inSan Carlos, CALIFORNIA (USA)
The Aliya PEF System is an advanced medical device used primarily for the surgical ablation of soft tissues, delivering high voltage, short-duration electrical energy to target cells. The system employs pulsed electric field technology to disrupt cellular homeostasis, leading to non-thermal programmed cell death while maintaining the integrity of the surrounding extracellular matrix. The system ...
Manufactured by:Xoft, Inc. based inSan Jose, CALIFORNIA (USA)
From a leading provider of electronic brachytherapy, skin eBx provides an effective, non-surgical, convenient treatment option with excellent clinical and cosmetic results for appropriately selected patients. Xoft offers patients and physicians a non-invasive alternative to surgery for NMSC treatment. With the Xoft System, painless, scar-free treatment of NMSC is possible with skin eBx, a form of ...
Manufactured by:Xoft, Inc. based inSan Jose, CALIFORNIA (USA)
From a leading provider of electronic brachytherapy, skin eBx provides an effective, non-surgical, convenient treatment option with excellent clinical and cosmetic results for appropriately selected patients. Xoft offers patients and physicians a non-invasive alternative to surgery for NMSC treatment. With the Xoft System, painless, scar-free treatment of NMSC is possible with skin eBx, a form of ...
Manufactured by:Xoft, Inc. based inSan Jose, CALIFORNIA (USA)
We are passionate about targeted cancer care expertly tailored to meet patients’ personalized needs. We designed the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to empower physicians with full confidence to precisely and effectively treat cancer and enable their patients to live healthy, high-quality lives. Xoft offers patients and physicians a simplified ...
by:Pure Biologics SA based inWroclaw, POLAND
Triple-negative breast cancer (TNBC) is a highly proliferative, rapidly growing, and aggressive form of cancer. TNBC can be further categorized into three types: Type 1 (also known as the “cold” type) is characterized by a tumor with low infiltration of immune cells into the tumor microenvironment; Type 2 is characterized by inactive cells of the innate immune system; Type 3 (also ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune therapies and cancer therapies. The video below provides more ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...